NICM
AGIO icon

Neo Ivy Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Neo Ivy Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,780
Closed -$149K – 422
2021
Q3 		$149K Buy
+2,780
New +$134K 0.17% 184
2020
Q3 		– Sell
-2,780
Closed -$149K – 450
2020
Q2 		$149K Buy
+2,780
New +$129K 0.17% 184

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Neo Ivy Capital Management's AGIO Position: Q4 2021 in Review

Neo Ivy Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q4 2021, closing a stake of 2,780 shares — an estimated $149K sold.

Neo Ivy Capital Management first reported a position in AGIO in Q2 2020 and held it in 2 quarters. The position peaked at $149K in Q3 2021. 160 funds tracked by Wall St. Rank hold AGIO as of Q4 2021.

  • Neo Ivy Capital Management reported no remaining Agios Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Neo Ivy Capital Management sold 2,780 Agios Pharmaceuticals shares in Q4 2021, an estimated $149K.
  • Neo Ivy Capital Management first reported a position in Agios Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Neo Ivy Capital Management's Agios Pharmaceuticals position peaked at $149K in Q3 2021.
  • 160 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2021.

Based on Neo Ivy Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.